Goldman Sachs analyst expects positive updates from Vertex's first Investor Day as a public company on March 19, reiterates ...
Latigo Biotherapeutics raises $150M Series B to advance Nav1.8 inhibitors for pain, competing with Vertex's Journavx.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback